Strongbridge Biopharma Stock Price, News & Analysis (NASDAQ:SBBP)

$2.68
-0.06 (-2.19 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$2.59
Now: $2.68
$2.87
50-Day Range
$2.32
MA: $2.62
$2.86
52-Week Range
$2.07
Now: $2.68
$6.52
Volume378,920 shs
Average Volume196,662 shs
Market Capitalization$145.22 million
P/E Ratio8.65
Dividend YieldN/A
Beta0.82
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.03 million
Cash Flow$0.8097 per share
Book Value$2.42 per share

Profitability

Net Income$31.85 million

Miscellaneous

Employees106
Market Cap$145.22 million
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.


Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings results on Wednesday, July, 31st. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.01. The biotechnology company earned $6.08 million during the quarter, compared to the consensus estimate of $4.82 million. Strongbridge Biopharma had a net margin of 181.52% and a return on equity of 49.92%. View Strongbridge Biopharma's Earnings History.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Strongbridge Biopharma.

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-20 million, compared to the consensus revenue estimate of $19.49 million.

What price target have analysts set for SBBP?

4 analysts have issued twelve-month price targets for Strongbridge Biopharma's stock. Their predictions range from $11.00 to $15.00. On average, they anticipate Strongbridge Biopharma's share price to reach $12.6667 in the next twelve months. This suggests a possible upside of 372.6% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

What is the consensus analysts' recommendation for Strongbridge Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Has Strongbridge Biopharma been receiving favorable news coverage?

Headlines about SBBP stock have trended negative on Friday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Strongbridge Biopharma.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a decline in short interest in August. As of August 31st, there was short interest totalling 1,125,500 shares, a decline of 16.2% from the July 31st total of 1,343,000 shares. Based on an average daily volume of 182,800 shares, the days-to-cover ratio is presently 6.2 days. Approximately 3.3% of the company's stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the folowing people:
  • Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 52)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 54)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.22%), D. E. Shaw & Co. Inc. (1.75%), River & Mercantile Asset Management LLP (0.85%), River & Mercantile Asset Management LLP (0.85%), Renaissance Technologies LLC (0.31%) and Stonepine Capital Management LLC (0.30%). View Institutional Ownership Trends for Strongbridge Biopharma.

Which institutional investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Wells Fargo & Company MN, Jefferies Group LLC and Stonepine Capital Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.

Which institutional investors are buying Strongbridge Biopharma stock?

SBBP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Bank of New York Mellon Corp, Susquehanna International Group LLP and Vanguard Group Inc.. View Insider Buying and Selling for Strongbridge Biopharma.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.68.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $145.22 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]


MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  249 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  512
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2019 by MarketBeat.com Staff

Featured Article: Operating Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel